Background <p>Gestational Diabetes Mellitus (GDM) is a common pregnancy complication that poses significant risks to both maternal and neonatal health, including preterm birth and macrosomia. Traditional GDM health education methods often lack clinical effectiveness due to insufficient personalized feedback and timely evaluation. This gap arises from the inadequate integration of nursing theories and quality management tools. This study explores the efficacy of combining King’s Theory of Goal Attainment with the Failure Modes and Effects Analysis (FMEA) and the Plan-Do-Check-Act (PDCA) cycle as a novel approach to health education for GDM patients.</p> Methods <p>This randomized controlled trial involved pregnant women attending tertiary hospitals in Fujian Province from March 1, 2022, to May 31, 2023. Participants (<i>n</i> = 118) were randomly assigned to either an innovative health education group (integrating King’s Theory and FMEA-PDCA) or a conventional education group. Outcomes were assessed pre- and post-intervention, including blood glucose levels, glycated hemoglobin (HbA1c), anxiety levels, quality of life, and pregnancy outcomes.</p> Results <p>The experimental group showed significantly improved fasting blood glucose, reduced anxiety, and enhanced quality of life (<i>P</i> &lt; 0.001). Additionally, the rate of cesarean sections was lower (<i>P</i> = 0.037) compared to the control group. However, no significant differences were observed in HbA1c levels (<i>P</i> = 0.671) or pregnancy-related complications (<i>P</i> &gt; 0.05).</p> Conclusion <p>The integration of King’s Theory and FMEA-PDCA in health education significantly improves educational outcomes and clinical results for GDM patients, presenting a promising strategy for clinical practice.</p> Trial registration <p>The study was retrospectively registered on 25 April 2024 (registration number: ChiCTR2400083435) by the Chinese Clinical Trial Registry: <a href="https://www.chictr.org.cn/">https://www.chictr.org.cn/</a>.</p>

错误:搜索内容不能为空,请输入英文关键词
错误:关键词超出字数限制,请精简
高级检索

Enhancing gestational diabetes mellitus education: a randomized controlled trial of King’s theory and FMEA-PDCA integration for improved patient outcomes

  • Canying Lin,
  • Qingzhen Guan,
  • Bilan Su,
  • Huayong Lin,
  • Yaoyao Xu,
  • Qifu Wu,
  • Li Ge

摘要

Background

Gestational Diabetes Mellitus (GDM) is a common pregnancy complication that poses significant risks to both maternal and neonatal health, including preterm birth and macrosomia. Traditional GDM health education methods often lack clinical effectiveness due to insufficient personalized feedback and timely evaluation. This gap arises from the inadequate integration of nursing theories and quality management tools. This study explores the efficacy of combining King’s Theory of Goal Attainment with the Failure Modes and Effects Analysis (FMEA) and the Plan-Do-Check-Act (PDCA) cycle as a novel approach to health education for GDM patients.

Methods

This randomized controlled trial involved pregnant women attending tertiary hospitals in Fujian Province from March 1, 2022, to May 31, 2023. Participants (n = 118) were randomly assigned to either an innovative health education group (integrating King’s Theory and FMEA-PDCA) or a conventional education group. Outcomes were assessed pre- and post-intervention, including blood glucose levels, glycated hemoglobin (HbA1c), anxiety levels, quality of life, and pregnancy outcomes.

Results

The experimental group showed significantly improved fasting blood glucose, reduced anxiety, and enhanced quality of life (P < 0.001). Additionally, the rate of cesarean sections was lower (P = 0.037) compared to the control group. However, no significant differences were observed in HbA1c levels (P = 0.671) or pregnancy-related complications (P > 0.05).

Conclusion

The integration of King’s Theory and FMEA-PDCA in health education significantly improves educational outcomes and clinical results for GDM patients, presenting a promising strategy for clinical practice.

Trial registration

The study was retrospectively registered on 25 April 2024 (registration number: ChiCTR2400083435) by the Chinese Clinical Trial Registry: https://www.chictr.org.cn/.